Diana Bilton is Honorary Clinical Senior Lecturer and Director of the Adult Cystic Fibrosis Service at Royal Brompton Hospital.
Diana trained in Manchester graduating in 1984.After completing general training she became a UK Cystic Fibrosis Trust research fellow with Professor Kevin Webb examining the influence of antioxidant status on pulmonary and pancreatic disease . This early research inspired Diana's career long interest in evaluating new diagnostic and therapeutic approaches to the continued vicious cycle of infection and inflammation in Cystic Fibrosis and Non CF Bronchiectasis.
Diana has been global chief investigator on trials of new therapies for Cystic Fibrosis and nonCF Bronchiectasis. Recent studies have included randomised trials of Inhaled Dry Powder Mannitol as well as investigation of novel inhaled antibiotic preparations.
Diana is joint PI with Dr Jane Davies of the European CF Society Clinical Trials Network site at Royal Brompton .
et al., 2018, Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry., Lancet Respir Med
Stephenson AL, Bilton D, 2018, The impact of National Cystic Fibrosis Registries: A review series., J Cyst Fibros
et al., 2018, Laboratory Diagnosis and Characterization of Fungal Disease in Patients with Cystic Fibrosis (CF): A Survey of Current UK Practice in a Cohort of Clinical Microbiology Laboratories., Mycopathologia
et al., 2018, The diagnosis and management of respiratory tract fungal infection in cystic fibrosis: A UK survey of current practice., Med Mycol
et al., 2018, Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data, Journal of Cystic Fibrosis, Vol:17, ISSN:1569-1993, Pages:218-227